about
Soluble Siglec-5 associates to PSGL-1 and displays anti-inflammatory activity.Auto-associative heparin nanoassemblies: a biomimetic platform against the heparan sulfate-dependent viruses HSV-1, HSV-2, HPV-16 and RSV.An improved strategy to recover large fragments of functional human neutrophil extracellular traps.Characterization of the Annonaceous acetogenin, annonacinone, a natural product inhibitor of plasminogen activator inhibitor-1.Mapping of the catalytic groove preferences of factor Xa reveals an inadequate selectivity for its macromolecule substrates.Unbalance between plasma levels of Protein Z and protein Z-dependent inhibitor in patients with colorectal and pancreatic cancer: a pilot study.Thrombin-activable factor X re-establishes an intrinsic amplification in tenase-deficient plasmas.Thrombomodulin favors leukocyte microvesicle fibrinolytic activity, reduces NETosis and prevents septic shock-induced coagulopathy in rats.The elusive role of the potential factor X cation-binding exosite-1 in substrate and inhibitor interactions.Inactivated antithombin as anticoagulant reversal in a rat model of cardiopulmonary bypass: a potent and potentially safer alternative to protamine.A chemically-modified inactive antithrombin as a potent antagonist of fondaparinux and heparin anticoagulant activity.An ADAM-10 dependent EPCR shedding links meningococcal interaction with endothelial cells to purpura fulminans.Inactivated antithrombins as fondaparinux antidotes: a promising alternative to haemostatic agents as assessed in vitro in a thrombin-generation assay.A fast capillary electrophoresis method to assess the binding affinity of recombinant antithrombin toward heparin directly from cell culture supernatants.Antithrombin is not protective against renal ischaemia-reperfusion injuryDevelopment of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivativesInflammation in deep vein thrombosis: a therapeutic target?
P50
Q30829904-CCFC9779-9E7B-4951-972B-8C2BDBAAB81FQ38994405-4AF6E621-D628-43EC-8FA8-ACB06289D1FDQ42229365-3FDABEB6-738A-4509-B613-50128D757470Q42364420-3BB625A1-14B4-4F04-8FF5-C55564C9E96DQ43941686-EF3624D2-1653-4B30-91E6-47FABBB79312Q43985190-7D030531-F2EF-47A5-BF53-BC93C091B523Q45887421-C61DF83B-4285-4FD3-B2E8-008EE50F2999Q47096499-C0A076BB-73B2-4231-975A-8A00F593D2DCQ47418397-920DE29D-1615-4124-8222-A265D84EA1DCQ48177040-CFEA95E5-EA3E-4814-AD72-92F600932663Q51071805-3CF8240C-54BC-4A90-8460-80A4CA01C425Q52431401-C8AECAB6-67BD-466D-B08B-CD63B41CE20EQ53061976-B916F39F-FCDD-46EB-8C77-B2AD59221863Q53546953-C7665AF4-B738-4FAF-8246-60F8A6A7FDA4Q61835245-DF3B7C92-8D3F-4AC5-8BA1-CFAE21EFAF4CQ61835383-D247BEB7-1CA3-443E-BC6B-E4FFE57CE2DBQ91315088-0A3394A1-1B32-430A-AD0C-1A6ACA36BCA9
P50
description
researcher
@en
wetenschapper
@nl
name
Elsa P Bianchini
@en
Elsa P Bianchini
@nl
type
label
Elsa P Bianchini
@en
Elsa P Bianchini
@nl
prefLabel
Elsa P Bianchini
@en
Elsa P Bianchini
@nl
P106
P31
P496
0000-0002-1370-5312